Oncology Medical News about ixabepilone, hepatobiliary cancers

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium
Investigational New Drugs, 08/20/09

Nimeiri HS et al. - In a study to evaluate the activity and safety of ixabepilone in a trial in pts with advanced cancers of the gallbladder, bile duct, and liver, it was reported that single-agent ixabepilone has limited activity in advanced hepatobiliary cancers.

Methods

Eligible pts had previously-untreated, histologically-proven unresectable hepatobiliary cancer.
Ixabepilone, 40 mg/m2, was administered intravenously over 3 hr every 21 days.

Results

54 pts (19 hepatocelluar carcinoma, 13 cholangiocarcinomas, 22 gallbladder carcinomas) were enrolled; 47 pts were evaluable for efficacy.
The objective response rate was 8.5%; 51% had stable disease.
Median overall survival was 7.0 mos and median progression-free survival was 2.6 mos.
Grade 3/4 toxicities included neutropenia (39%), fatigue (9%), allergic/hypersensitivity reaction (4%), and sensory neuropathy (4%).

<< Previous
Low drug resistance to both platinum and taxane chemotherapy on...

Next >>
Initial dose intensity has limited impact on the outcome of ABVD...

Real-time and the in vivo detection of minute cancer invasion to the portal-superior mesenteric vein using contact endoscopy during a pancreatic cancer resection
The American Journal of Surgery, 11/06/09 Relevance Score: 67%

Clinical importance of B7-H3 expression in human pancreatic cancer
British Journal of Cancer, 10/26/09 Relevance Score: 67%

Association of Breast Cancer Susceptibility Variants with Risk of Pancreatic Cancer
Cancer Epidemiology, Biomarkers & Prevention, 10/23/09 Relevance Score: 67%

Elevated Cancer Mortality in the Relatives of Patients with Pancreatic Cancer
Cancer Epidemiology, Biomarkers & Prevention, 10/23/09 Relevance Score: 67%

Update and Review of the Multidisciplinary Management of Stage IV Colorectal Cancer with Liver Metastases
World Journal of Surgical Oncology, 10/02/09 Relevance Score: 67%